Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06374602

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Led by Saint Petersburg State University, Russia · Updated on 2025-09-05

20

Participants Needed

1

Research Sites

117 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.

CONDITIONS

Official Title

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Immunohistochemically confirmed anaplastic thyroid cancer not suitable for complete (R0-R1) surgery
  • Age 18 years or older
  • Functional status ECOG 0-2
  • Adequate function of internal organs and bone marrow
  • Ability to provide written informed consent
Not Eligible

You will not qualify if you...

  • Presence of BRAF V600 gene mutation without prior targeted therapy with BRAF/MEK inhibitors
  • Clinically significant bleeding such as hemoptysis or gastrointestinal bleeding
  • Tumor invasion into large blood vessels
  • Open wounds or fistulas
  • Contraindications to study drugs
  • Poor functional status ECOG 3-4
  • Continuous use of immunosuppressive therapy
  • Prior treatment with investigational drugs
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Saint Petersburg State University Hospital

Saint Petersburg, Russia, 190020

Actively Recruiting

Loading map...

Research Team

I

Ilya Sleptsov, MD

CONTACT

E

Ernest Dzhelialov

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here